Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
Titel:
Evaluation of Anaplastic Lymphoma Kinase (ALK) Inhibitor Brigatinib [AP26113] in Patients (PTS) with Alk+ Non–Small Cell Lung Cancer (NSCLC) and Brain Metastases
Auteur:
Kerstein, D. Gettinger, S. Gold, K. Langer, C.J. Shaw, A.T. Bazhenova, L.A. Salgia, R. Dorer, D.J. Conlan, M.G. Camidge, D.R.